The FDA’s Quality Management System Regulation (QMSR) took effect on February 2 2026, replacing the old Quality System Regulation and incorporating ISO 13485:2016 and ISO 9000:2015 by reference. The new rule harmonizes U.S. device quality management with international standards and aims to reduce regulatory burden for manufacturers that operate globally. It centers risk management and quality culture; inspectors were retrained and early inspections show they are scrutinizing how manufacturers identify and mitigate risks across the product life cycle. This harmonization should streamline compliance for established companies while giving startups clearer guidance, but all firms must update procedures and embed risk‑based thinking.
“One of the things that underlines 1345 is explicitly risk management, and how you have to involve risk management in your quality systems”.
Source:
Medical Device Companies Must Navigate Historic FDA Rule Change
The QMSR also grants FDA inspectors access to manual reviews, internal audits and supplier audits that were previously protected. This change will allow investigators to examine how management makes decisions, potentially leading to new enforcement findings. ISO 13485 introduces a requirement to protect patient information contained in complaint files, and companies must document decisions carefully because inspections are retrospective and the FDA does not plan to be lenient during the transition. Harmonization with ISO 13485 may pressure European notified bodies to match the FDA’s level of scrutiny, so device makers should expect more probing inspections and align their quality systems accordingly.
Key Takeaway for Manufacturers
The QMSR harmonizes U.S. device quality management with ISO 13485, making risk management and quality culture central while expanding FDA access to internal records; manufacturers must embed risk‑based processes and update documentation to meet the new, globally aligned standard.
Need help navigating evolving FDA requirements?
Dawa Medical works with manufacturers to simplify regulatory processes, support U.S. market entry, and build strong distribution strategies.
Contact Dawa Medical
